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Dahai Yu*, Zhanzheng Zhao*†, Uchechukwu Levi Osuagwu, Karen Pickering, John Baker, Richard Cutfield, Brandon J Orr-Walker, Yamei Cai, 
David Simmons†
Summary
Background Type 2 diabetes affects Indigenous and non-European populations disproportionately, including in 
New Zealand, where long-term temporal trends in cause-specific clinical outcomes between Māori, Pacific, and 
European people remain unclear. We aimed to compare the rates of mortality and hospital admission between Māori, 
Pacific, and European patients with type 2 diabetes in Auckland, New Zealand, over a period of 24 years. 
Methods In this retrospective, population-based, longitudinal cohort study, we identified a cohort of patients (aged 
35–84 years) with type 2 diabetes enrolled between Jan 1, 1994, and July 31, 2018, to the primary care audit programme, 
the Diabetes Care Support Service (DCSS) in Auckland, New Zealand. Patients with type 1 diabetes, prediabetes, and 
gestational diabetes were excluded. We linked data from the DCSS with national death registration, hospital admission, 
pharmaceutical claim, and socioeconomic status databases. Patients were followed up until death or July 31, 2018 (date of 
last enrolment to the DCSS). Incident clinical events (all-cause mortality, cardiovascular mortality, cancer mortality, 
cardiovascular hospital admission, cancer hospital admission, and end-stage renal disease hospital admission) were 
identified. Event rates were stratified by ethnic group, age group, sex, socioeconomic status, and time period (<1998, 
1999–2013, 2004–08, 2009–13, and 2014–18). Incidence rate ratios (IRRs) and absolute risk differences were adjusted for 
sex, age, smoking status, obesity, socioeconomic status, and time period by use of age-period-cohort modelling.
Findings Between Jan 1, 1994, and July 31, 2018, 45 072 patients with type 2 diabetes (21 936 [48·7%] female; mean age 
56·7 years [SD 13·8]) were enrolled in the DCSS and followed up for a median of 9·7 years (IQR 5·8–13·6). 
16 755 (37·2%) were European, 7093 (15·7%) were Māori, and 12 044 (26·7%) were Pacific patients. Despite a similar 
temporal trend (decreasing mortality and increasing hospital admissions) across the three ethnic groups, Māori and 
Pacific patients had consistently higher hospital admission rates than European patients. Māori but not Pacific 
patients had higher adjusted IRRs for all-cause mortality (1·96 [95% CI 1·80–2·14]), cardiovascular mortality (1·93 
[1·63–2·29]) and cancer mortality (1·64 [1·40–1·93]) rates compared with European patients.
Interpretation Compared with European patients, poorer health outcomes have persisted among Māori and Pacific 
people with type 2 diabetes for more than 20 years. New policies supporting prevention and more intensive 
management of type 2 diabetes are urgently needed. Research into the biological and societal mechanisms underlying 
these disparities, and the associated differences between Māori and Pacific patients is also needed.
Funding Counties Manukau Health and Middlemore Foundation.
Copyright © 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 
license.
Introduction
Type 2 diabetes affects approximately 422 million people 
worldwide, including 240 000 people in New Zealand. 
Despite improvements in diabetes therapies over the past 
two decades, mortality remains high,1 with dis parities 
associated with ethnicity and socioeconomic status.2 The 
cost of hospital admissions associated with type 2 diabetes 
is high; in the USA, this cost is predicted to reach more 
than $622 billion per year by 2030.3 The economic costs of 
type 2 diabetes are expected to increase, with a projected 
increase in the prevalence of this condition of 54% by 
2030.3 Consequently, attempts to reduce the substantial 
social, health, and economic burden of type 2 diabetes 
have become a top public health priority.4
The 2–4-times greater risk of type 2 diabetes among 
Māori and Pacific people in New Zealand was first 
reported in the 1960s;5 Māori and Pacific people also 
have an earlier age of onset and a 2–4-times higher 
risk of diabetes-related complications compared with 
New Zealanders of European descent. Biological 
differences (eg, body composition),5 health inequities,6 or 
both have been proposed as possible mechanisms 
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underlying these disparities. Contemporary population-
level data on emerging outcome trends among different 
ethnic groups of people with type 2 diabetes in New 
Zealand are not available, and cause-specific mortality and 
hospital admission rates in people with type 2 diabetes will 
enable demand projections. Such trends are also likely to 
inform our understanding of the global epidemiology of 
type 2 diabetes. We aimed to investigate whether ethnic 
differences in mortality and hospital admission rates 
among patients with type 2 diabetes in New Zealand have 
persisted. We also aimed to estimate the risk difference 
of these outcomes between ethnic groups using a novel 
age-period-cohort analysis.
Methods
Study design and population
We did a retrospective, population-based, longitudinal 
cohort study of Māori, Pacific, and European patients (aged 
35–84 years) with type 2 diabetes enrolled between Jan 1, 
1994, and July 31, 2018 to the Diabetes Care Support Service 
(DCSS). The DCSS, a primary care audit programme 
established in 1991, audits general practice diabetes 
management in south, east, and west Auckland to 
improve standards of care.7 We linked data from the DCSS 
with national death registration, hospital admission, 
pharma ceutical claim, and socioeconomic status databases 
to identify a cohort of patients with type 2 diabetes in 
Auckland, New Zealand. All patients were included in 
the audit. Patients from other individual ethnic groups 
were excluded from the ethnic group-specific analyses 
due to insufficient numbers. The longitudinal, linked, 
anonymised DCSS database included data on patient 
demographics, risk factors, clinical measurements, diag-
nosed diabetes complications, and diabetes medications, 
all of which have been validated through enumeration 
assessment and internal quality control policies, with 
auditors regularly cross-checking data, and undertaking 
random and routine sampling or data entry checks, and 
active data management (eg, checking unusual num bers, 
ranking columns, and checking duplicates).7–9 Pharma-
ceutical claims data included all prescriptions issued for 
patients, and was used to cross-validate the prescription 
data in the DCSS. Only pharmaceutical claims data after 
2006 were available for linkage. Historical claims before 
Research in context
Evidence before this study
In New Zealand, there is an epidemic of type 2 diabetes leading 
to increasing health-care utilisation. Health disparities between 
Māori (Indigenous New Zealanders), Pacific, and European 
ethnic groups in New Zealand are well known. However, the 
extent of the disparities in mortality and hospital admission 
rates between Māori, Pacific, and European New Zealanders 
with type 2 diabetes in the 21st century is unknown. We 
searched PubMed using the search terms “Māori” and “type 2 
diabetes” in different combinations with “surviv*”, “rate*”, 
“outcome*”, “mortality”, “death*”, “hospital*”, “prognos*”, and 
“trend*”. We searched for primary research published between 
Jan 1, 2000, and Dec 5, 2019, written in English, comparing 
outcome trends in type 2 diabetes between Indigenous and 
European patients in New Zealand. We found 152 studies, and 
reviewed the full text of relevant articles to assess their 
appropriateness for inclusion. Most studies addressed the 
general population and focused on short-term outcomes. 
We found no studies reporting cause-specific mortality or 
hospital admission trends over the last two decades among 
Māori, Pacific, and European patients with type 2 diabetes in 
New Zealand.
Added value of this study
The Diabetes Care Support Service (DCSS) was a long-running 
audit of diabetes management in primary care. By linking the 
DCSS with national death registration, national hospital 
admissions, national pharmaceutical claims, and national 
primary care databases to identify a cohort of patients with 
type 2 diabetes, we were able to evaluate long-term health 
disparities between Māori, Pacific, and European ethnic groups 
in New Zealand between 1994 and 2018. Cause-specific 
mortality rates and incidence rates of hospital admissions were 
consistently higher in Māori patients than in European and 
Pacific patients with type 2 diabetes over the past 20 years. 
These health disparities persisted after adjusting for birth 
cohort and period effects, and for population confounders (age, 
sex, smoking status, obesity, socioeconomic status, and time 
periods). Most cause-specific mortality rates between Pacific 
and European patients with type 2 diabetes did not differ 
significantly over the same time period. Hospital admission 
rates were significantly higher in both Māori and Pacific 
patients than in European patients.
Implications of all the available evidence
Disparities in mortality and hospital admission rates persist 
between Māori, Pacific, and European patients with type 2 
diabetes in New Zealand, and remain a substantial social, 
health, and economic burden. These health disparities for type 
2 diabetes were not driven by population-level confounders, 
such as age, sex, smoking status, obesity, socioeconomic 
status, birth cohort effects, or time period effects. The 
perpetuation of these poor outcomes in patients with type 2 
diabetes, particularly among Māori patients, over such a long 
period of time, calls for the introduction of new, more 
intensive, approaches for the early recognition and 
management of this condition, while broader strategies are 
needed to address social disparities and prevention. Differences 
in outcomes between Māori and Pacific patients with type 2 
diabetes warrant further research into the underlying 
biological mechanisms, and the role of current or historical 
inequities.
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2006 were not linked because National Health Index 
numbers were not universal until 2006. Data for all 
patients from their first DCSS enrolment date (Jan 1, 1994) 
up to July 31, 2018, (date of last enrolment to the DCSS) 
were included in the study.
The North Health Ethics Committee approved the DCSS 
for research purposes in 1992, and then as an ongoing 
audit in 1996 (92/006). Ethics review was waived by the 
New Zealand Health and Disability Ethics Committees on 
March 25, 2019. Anonymised data were used for this 
analysis. Signed consent to participate was provided by an 
authorised signatory for each general practice.
Procedures
Type 2 diabetes was defined by primary care record coding, 
with validation by trained diabetes auditors. Baseline 
characteristics included smoking, diabetes duration, body-
mass index (BMI), blood pressure, glycated haemoglobin 
(HbA1c), blood lipids, and anti hyper tensive, antidiabetes, 
statin, and antiplatelet or anticoagulant treatment (or 
both).
Patients were categorised into exposure groups by 
ethnicity (Māori, European, and Pacific); age (<35 years, 
35–44 years, 45–54 years, 55–64 years, 65–74 years, 
75–84 years and ≥85 years); sex; and socioeconomic 
status. Māori (Indigenous Polynesian) patients were 
defined as those with any Māori ancestry, and Pacific 
patients (93% Polynesian) were defined as those with any 
Pacific ancestry except Māori. As only six all-cause death 
events occurred in those aged <35 years, and the numbers 
of Māori (n=31) and Pacific patients (n=67) aged ≥85 years 
were low, analyses in these two strata were excluded.
The area deprivation indicator from the Department of 
Public Health, University of Otago (Otago, New 
Zealand), NZDep2013 was used to define socioeconomic 
status. NZDep2013 provides an Index of Multiple 
Deprivation (IMD) score for each New Zealand 
meshblock (Statistics New Zealand-defined geographical 
units, each of which included a median of approximately 
81 people in 2013).10 NZDep2001, NZDep2006, and 
NZDep2013 scores were compared at a patient level to 
observe shifts in socio economic status over time 
(appendix pp 1–5). As consistent stability in socio-
economic status was observed using NZDep2013, this 
index was chosen for analyses. The NZDep2013 scale of 
deprivation ranges from 1 to 10, and divides New Zealand 
into tenths of the distribution of the first principal 
component scores. To maintain statistical power, the 
IMD was redefined by re-ranking NZDep2013 into 
5 groups: IMD-1 (least deprived; NZDep2013 score 1–2), 
IMD-2 (NZDep2013 score 3–4), IMD-3 (NZDep2013 
score 5–6), IMD-4 (NZDep2013 score 7–8), and IMD-5 
(most deprived; NZDep2013 score 9–10).
Outcomes
The primary objective was to compare all-cause, cardio-
vascular, and cancer mortality rates, and the incidence 
rates of hospital admission due to cardio vascular disease, 
cancer, and end-stage renal disease (ESRD) between 
Māori, Pacific, and European patients with type 2 
diabetes. Sensitivity analyses were done by adjusting for 
confounders.
The linked national death registration database includes 
all deaths registered in New Zealand and was used to 
obtain the date and cause of death of patients in our 
cohort. The count of individual deaths was used to 
estimate mortality. Hospital admission was defined as all 
non-elective admissions occurring after, but not on, the 
date of enrolment to the DCSS. The linked national 
hospital admissions database, which includes all inpatient 
hospital admissions in New Zealand, provided the date 
and cause of hospital admission (defined as the primary 
cause of hospital admission). The overall number of 
hospital admissions (events) were counted for each 
patient, with follow-up until death or the end of the study 
(July 31, 2018). All clinical events were defined by the 
primary International Classification of Disease (ICD)-
ninth edition and ICD-tenth edition (appendix p 6). 
Incident clinical events (all-cause mortality, cardiovascular 
mortality, cancer mortality, cardiovascular hospital 
admission, cancer hospital admission, and ESRD hospital 
admission) between Jan 1, 1994 and Dec 31, 2018, were 
identified.
Statistical analysis
Descriptive statistics are presented as numbers and 
proportions for dichotomous variables, and as mean 
(SD) or median (IQR) for continuous variables. Incident 
clinical event rates with 95% CIs are shown for the whole 
cohort, and stratified by ethnic group, age group, sex, 
socioeconomic status, and time period (<1998, 1999–2013, 
2004–08, 2009–13, and 2014–18).
Māori and Pacific patients were compared with 
European patients by use of Poisson regression models 
(with 95% CIs), to estimate absolute risk differences and 
the incidence rate ratio (IRR) of clinical events, adjusting 
for population-level confounders overall, and by sex, age, 
smoking, obesity (defined as a BMI of ≥30 kg/m²), 
socioeconomic status, and time period.
We modelled age-period-cohort effects on clinical events 
from 1994 to 2018. Since the birth cohort is defined as the 
time period of the study minus the age of the patient, 
standard regression models to simultaneously estimate 
the additive effects of age, time period, and cohort effects 
cannot achieve a unique solution. Two approaches were 
therefore used to provide a robust check on the results of 
the age-period-cohort analysis.11 The first approach to 
overcome dependency, was to estimate a variable (referred 
to as a drift variable) for the overall linear trend in clinical 
event rates that cannot be attributable uniquely to either 
time period or cohort effects. Derivation from linearity 
(referred to as curvature), which can be uniquely 
attributable to time period or cohort effects, and is not 
dependent on any model constraint, was then estimated as 
See Online for appendix
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time period or cohort effects. We estimated clinical event 
rates using parametric smooth functions based on natural 
splines with five knots for age, time period, and cohort 
variable to detect non-linear effects.
To address the effect of population-level confounders 
as a sensitivity analysis, age-period-cohort analyses were 
re-run by sex, socioeconomic status, smoking status, and 
obesity for each clinical event. All statistical analyses 
were done by use of Stata MP 15.1.
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to 
all the data and had final responsibility for the decision to 
submit for publication.
Results
45 072 patients with type 2 diabetes were enrolled in the 
DCSS between Jan 1, 1994, and July 31, 2018. 21 936 
(48·7%) were female and the mean age was 56·7 years 
(SD 13·8). Patients were followed up for a median 
of 9·7 years (IQR 5·8–13·6). The characteristics of the 
16 755 (37·2%) European, 7093 (15·7%) Māori, and 
12 044 (26·7%) Pacific patients are shown in table 1. 
Median follow-up was 9·5 years (IQR 5·3–13·4) for 
European patients, 9·9 years (5·9–14·0) for Māori 
patients, and 9·8 years (5·9–14·2) for Pacific patients. 
9180 (20·4%) patients from Africa, south Asia, east Asia, 
and the Middle East were excluded from ethnicity-specific 
analyses. Compared with Māori and Pacific patients, 
European patients were older, had the lowest deprivation 
scores, included fewer women and fewer current 
smokers, and had the lowest BMI, HbA1c, and diastolic 
blood pressure, but the highest systolic blood pressure. 
There were no differences in diabetes duration or 
cholesterol concen trations between the three ethnic 
groups. Antihypertensive and statin therapy use was 
lowest among Pacific patients, and insulin therapy was 
lowest among European patients. Māori and Pacific 
patients were similar in terms of age, sex, and BMI. Māori 
patients had the highest proportion of current smokers, 
even after adjusting for socioeconomic status. Compared 
with Māori and European ethnic groups, the Pacific 
group had the highest proportion of patients in the most 
deprived category, but systolic and diastolic blood 
pressure was lower and HbA1c was higher.
The overall crude all-cause mortality rate in all patients 
increased from 12·62 deaths per 1000 person-years 
(95% CI 11·05–14·37) in 1994–98, to 19·35 deaths per 
1000 person-years (18·00–20·77) in 2004–08, before 
decreasing to 16·90 deaths per 1000 person-years 
(15·85–17·99) in 2009–13, and 9·90 deaths per 
1000 person-years (9·14–10·71) in 2014–18 (table 2). 
Although the trend was similar across the three ethnic 
groups by sex, age group, socioeconomic status 
(appendix pp 7–8), and smoking and obesity status 
(appendix p 15), the overall all-cause mortality rate was 
highest among Māori patients and lowest among Pacific 
patients at each time period, both overall and within 
subgroups.
All patients 
(n=45 072)
European 
patients 
(n=16 755)
Māori patients 
(n=7093)
Pacific patients 
(n=12 044)
Age at enrolment, years 56·7 (13·8) 62·2 (13·2) 51·5 (12·6) 52·8 (12·8)
Age distribution, years 
<35 550 (1·2%) 75 (0·4%) 168 (2·4%) 231 (1·9%)
35–44 6351 (14·1%) 1228 (7·3%) 1509 (21·3%) 2226 (18·5%)
45–54 11 736 (26·0%) 3135 (18·7%) 2336 (32·9%) 3858 (32·0%)
55–64 12 372 (27·4%) 4577 (27·3%) 1958 (27·6%) 3330 (27·6%)
65–74 9087 (20·2%) 4526 (27·0%) 863 (12·2%) 1819 (15·1%)
75–84 4147 (9·2%) 2633 (15·7%) 228 (3·2%) 513 (4·3%)
≥85 829 (1·8%) 581 (3·5%) 31 (0·4%) 67 (0·6%)
Sex
Female 21 936 (48·7%) 7560 (45·1%) 3613 (50·9%) 6437 (53·5%)
Male 23 136 (51·3%) 9195 (54·9%) 3480 (49·1%) 5607 (46·5%)
IMD group (NZDep13 scale)*
IMD-1 (1 or 2) 5503 (12·2%) 3235 (19·3%) 277 (3·9%) 329 (2·7%)
IMD-2 (3 or 4) 5428 (12·0%) 2857 (17·1%) 515 (7·3%) 596 (4·9%)
IMD-3 (5 or 6) 5006 (11·1%) 2615 (15·6%) 718 (10·1%) 643 (5·3%)
IMD-4 (7 or 8) 10 709 (23·8%) 4360 (26·0%) 1665 (23·5%) 2502 (20·8%)
IMD-5 (9 or 10) 18 426 (40·9%) 3688 (22·0%) 3918 (55·2%) 7974 (66·2%)
Current smoker 6360 (14·1%) 1812 (10·8%) 2124 (30·0%) 1737 (14·4%)
Duration of having diabetes, 
years 
4·8 (1·2) 4·7 (1·2) 5·0 (1·4) 4·9 (1·1)
Body-mass index, kg/m² 32·5 (7·4) 31·2 (6·5)  35·9 (7·8)  35·0 (7·4)
Obesity 26 867 (59·6%) 8960 (53·5%) 5596 (78·9%) 8946 (74·3%)
Blood pressure, mm Hg
Systolic 135 (18) 137 (18)  135 (19)  132 (18)
Diastolic 81 (11) 80 (10)  83 (12)  82 (11)
HbA1c 7·6% (4·0) 7·1% (3·7) 8·1% (4·2) 8·3% (4·2)
HbA1c, mmol/mol 60 (20) 54 (17) 65 (22) 67 (22)
Total cholesterol, mmol/L 5·1 (1·2) 5·0 (1·2) 5·2 (1·2) 5·0 (1·2)
Triglyceride, mmol/L 2·2 (1·5) 2·2 (1·4) 2·6 (1·6) 2·1 (1·6)
LDL, mmol/L 2·5 (0·9) 2·5 (0·9) 2·6 (1·0)  2·6 (1·0)
HDL, mmol/L 1·2 (0·3) 1·2 (0·3)  1·1 (0·3) 1·2 (0·3)
Antihypertensive treatment 30 165 (66·9%) 11 687 (70·0%) 5060 (71·3%) 8070 (67·0%)
Statin treatment  24 676 (54·8%) 9417 (56·2%) 4197 (59·2%) 6380 (53·0%)
Antidiabetes treatment†
Oral antidiabetes drug and 
insulin 
7130 (15·8%) 2510 (15·0%) 1398 (19·7%) 2182 (18·1%)
Oral antidiabetes drug only 26 968 (59·8%) 9337 (55·7%) 4180 (58·9%) 7569 (62·8%)
Insulin only 4922 (10·9%) 1776 (10·9%) 994 (14·0%) 1237 (10·3%)
Antiplatelet or anticoagulant 
treatment
1072 (2·4%) 574 (3·4%) 198 (2·8%) 182 (1·5%)
Data are n (%) or mean (SD). IMD=Index of Multiple Deprivation. HbA1c=glycated haemoglobin. *IMD, defined by the 
NZDep13 Index of Deprivation, was used to divide patients into groups ranging from IMD-1 (least deprived) to IMD-5 
(most deprived). †Neither GLP-1 receptor agonists nor SGLT2 inhibitors are available in New Zealand, despite evidence 
to show that they improve outcomes in patients with type 2 diabetes.
Table 1: Characteristics of study participants with type 2 diabetes at enrolment to the Diabetes Care 
Support Service
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Compared with European patients, the adjusted overall 
IRR for all-cause mortality was 1·96 (95% CI 1·80–2·14) 
in Māori patients, with an adjusted absolute risk 
difference of 22·85 per 1000 person-years (95% CI 
19·03–25·77; table 3). Similar ethnic differences were 
also found by sex, age, smoking, obesity, socioeconomic 
status, and time period (appendix pp 19–20). However, 
the adjusted IRRs for all-cause mortality in Pacific 
patients compared with European patients indicated that 
this outcome did not differ significantly between the two 
ethnic groups (appendix pp 19–20). The adjusted absolute 
risk difference for all-cause mortality in Pacific patients 
compared with European patients was marginally higher 
in some subgroup analyses (eg, in men), but was 
significantly lower in the 2014–18 cohort (appendix 
pp 21–22).
The overall crude cardiovascular mortality rate decreased 
from 3·38 deaths per 1000 person-years (95% CI 
2·59–4·34) in 1994–98 to 2·00 deaths per 1000 person-
years (1·67–2·37) in 2014–18 (table 2). Although the 
pattern fluctuated between time periods, cardiovascular 
mor tality rate patterns were similar across the three ethnic 
groups, irrespective of sex, age, socioeconomic status, 
smoking status, and obesity (appendix pp 8–9, 15–16). The 
cardio vascular mortality rate was highest among Māori 
patients and lowest among Pacific patients in each time 
period and by sex, age group, smoking status, and obesity 
(appendix pp 8–9, 15–16).
Compared with European patients, the adjusted IRR 
for cardiovascular mortality in Māori patients was 1·93 
(95% CI 1·63–2·29), with an absolute risk difference of 
6·97 deaths per 1000 person-years (95% CI 5·14–8·80; 
table 3). These ethnic differences were also observed 
when patients were grouped by sex, age, smoking status, 
obesity, socioeconomic status, and time period (appendix 
pp 19–20). However, the adjusted IRRs and absolute risk 
differences for cardiovascular mortality in Pacific patients 
indicated that the incidence of this outcome was not 
significantly different to that in European patients 
(appendix pp 21–22).
The overall cancer mortality rate in the whole cohort 
increased from 2·29 deaths per 1000 person-years (95% CI 
1·65–3·10) in 1994–98 to 5·41 deaths per 1000 person-years 
(4·86–6·01) in 2004–08, before de creasing to 3·46 deaths 
per 1000 person-years (3·02–3·95) in 2014–18 (table 2). 
Although the pattern was similar across ethnic groups by 
sex, age (appendix pp 9–10), socioeconomic status, 
smoking, and obesity (appendix pp 16–17), the overall 
All-cause mortality Cardiovascular 
mortality
Cancer mortality Cardiovascular hospital 
admission
Cancer hospital 
admission
End-stage renal 
disease hospital 
admission
All patients
<1998 12·62 (11·05–14·37) 3·38 (2·59–4·34) 2·29 (1·65–3·10) 24·94 (24·38–25·50) 13·22 (12·40–14·09) 1·11 (0·81–1·49)
1999–2003 19·35 (18·00–20·77) 5·88 (5·16–6·69) 5·28 (4·59–6·04) 51·16 (50·61–51·72) 36·82 (35·90–37·76) 17·83 (16·97–18·72)
2004–08 17·40 (16·39–18·45) 4·02 (3·55–4·54) 5·41 (4·86–6·01) 76·93 (76·28–77·59) 66·80 (65·75–67·86) 27·19 (26·28–28·14)
2009–13 16·90 (15·85–17·99) 4·12 (3·62–4·67) 5·22 (4·65–5·84) 131·63 (130·40–132·86) 119·94 (118·16–121·74) 42·40 (41·06–43·78)
2014–18 9·90 (9·14–10·71) 2·00 (1·67–2·37) 3·46 (3·02–3·95) 264·87 (262·07–267·69) 210·20 (207·13–213·30) 75·34 (73·36–77·36)
European patients
<1998 12·32 (10·15–14·83) 3·83 (2·67–5·33) 1·86 (1·08–2·98) 26·86 (26·05–27·69) 11·97 (10·95–13·07) 0·87 (0·49–1·44)
1999–2003 20·83 (18·80–23·02) 7·00 (5·85–8·31) 6·03 (4·96–7·25) 55·28 (54·43–56·14) 36·78 (35·56–38·04) 12·21 (11·11–13·39)
2004–08 19·35 (17·83–20·97) 4·98 (4·22–5·82) 6·43 (5·57–7·38) 83·49 (82·48–84·50) 67·56 (66·18–68·97) 21·86 (20·64–23·14)
2009–13 18·27 (16·71–19·94) 4·63 (3·87–5·50) 5·94 (5·07–6·91) 128·99 (127·16–130·84) 117·90 (115·57–120·26) 37·38 (35·52–39·30)
2014–18 11·33 (10·11–12·65) 2·10 (1·60–2·70) 4·96 (4·18–5·85) 266·88 (262·50–271·30) 253·37 (248·62–258·20) 71·35 (68·45–74·35)
Māori patients
<1998 15·17 (11·02–20·36) 2·74 (1·18–5·39) 3·76 (1·88–6·72) 25·57 (24·31–26·88) 19·02 (16·64–21·63) 1·34 (0·67–2·39)
1999–2003 25·08 (21·32–29·31) 6·90 (5·02–9·27) 5·80 (4·09–8·00) 50·07 (48·86–51·31) 40·18 (37·82–42·65) 27·21 (24·93–29·66)
2004–08 22·48 (19·68–25·58) 5·45 (4·13–7·06) 5·93 (4·55–7·60) 76·16 (74·74–77·59) 70·50 (67·84–73·24) 39·68 (37·20–42·27)
2009–13 25·18 (22·08–28·60) 5·92 (4·48–7·67) 7·59 (5·95–9·55) 135·23 (132·61–137·90) 138·89 (134·26–143·64) 57·92 (54·36–61·66)
2014–18 13·08 (10·92–15·54) 3·07 (2·09–4·36) 3·88 (2·76–5·30) 290·98 (284·30–297·78) 209·36 (201·77–217·17) 102·13 (96·49–108·02)
Pacific patients
<1998 11·15 (7·97–15·18) 1·94 (0·78–3·99) 2·22 (0·96–4·36) 19·54 (18·41–20·72) 14·94 (12·79–17·36) 1·36 (0·72–2·32)
1999–2003 14·58 (12·19–17·30) 3·97 (2·78–5·49) 3·64 (2·50–5·11) 42·26 (41·18–43·36) 32·90 (30·89–35·00) 21·22 (19·39–23·18)
2004–08 12·34 (10·52–14·39) 1·72 (1·09–2·58) 3·30 (2·40–4·43) 65·97 (64·68–67·27) 56·79 (54·41–59·25) 29·61 (27·64–31·67)
2009–13 14·49 (12·34–16·91) 3·01 (2·09–4·21) 3·46 (2·46–4·73) 131·99 (129·35–134·68) 121·95 (117·22–126·82) 51·58 (48·34–54·98)
2014–18 8·19 (6·82–9·76) 1·74 (1·15–2·53) 1·55 (0·99–2·31) 264·40 (258·93–269·95) 154·33 (148·57–160·25) 82·90 (78·72–87·24)
All data are incidence rates per 1000 person-years (95% CI).
Table 2: Incidence rate (per 1000 person-years) of clinical outcomes, stratified by ethnicity and time period
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cancer mortality rate was highest among Māori patients 
and lowest among Pacific patients in each time period.
Compared with European patients, the adjusted overall 
IRR for cancer mortality was 1·64 (95% CI 1·40–1·93) 
in Māori patients, with an absolute risk difference 
of 3·08 per 1000 person-years (2·25–3·92; table 3). These 
ethnic differences were also observed when patients were 
grouped by sex, age, socioeconomic status, smoking 
status, obesity and time period (appendix pp 19–20). 
However, the adjusted IRRs and absolute risk differences 
for cancer mortality in Pacific people indicated that the 
incidence of this outcome was similar to that in European 
patients (appendix pp 21–22).
Overall, ethnic and age-specific crude incidence rates of 
cardiovascular hospital admissions increased substantially 
over time (table 2 and appendix pp 10–11, 17–18). The 
incidence rates of this outcome were higher among 
European patients than Māori patients in 1999–2008, 
whereas the opposite trend was observed from 2009 
onwards. Compared with European patients, the adjusted 
overall IRR for cardiovascular hospital admission was 
higher among Māori patients (1·26 [95% CI 1·25–1·28]) 
and Pacific patients (1·09 [1·07–1·10]; table 3) across 
the different time periods (appendix pp 19–20). These 
ethnic differences were largely present over the whole 
time period (1998–2018) when patients were grouped by 
sex, socioeconomic status, obesity, and smoking status 
(appendix pp 19–22). Even though the adjusted overall 
absolute risk difference reflected the adjusted overall IRR 
for cardio vascular hospital admission, the absolute risk 
differences in Pacific patients were generally significantly 
lower than in Māori patients in all subgroup analyses 
(appendix pp 21–22).
The overall, ethnic and age-specific incidence rates of 
cancer hospital admissions increased substantially over 
time (table 2 and appendix pp 11–12, 17). The adjusted 
IRRs of this outcome were higher among Māori and 
Pacific patients (table 3 and appendix pp 19–20); however, 
Māori patients had a greater adjusted absolute risk 
difference for cancer hospital admission than European 
and Pacific patients overall, and when patients were 
grouped by sex, age, socioeconomic status, smoking status, 
obesity, and time period (table 3 and appendix pp 21–22).
The overall, ethnic, sex, and age-specific incidence 
rates of ESRD hospital admission increased substantially 
over time, with low incidence rates of this outcome 
before 1998 (table 2 and appendix pp 13–14, 18). When 
compared with European patients, the incidence rates of 
ESRD hospital admission were generally highest among 
Māori patients (IRR 2·05 [95% CI 1·96–2·14]; absolute 
risk difference 31·44 per 1000 person-years [95% CI 
29·67–33·21]), followed by Pacific patients (1·59 
[1·52–1·67]; 17·29 per 1000 person-years [16·12–18·46]; 
table 3). These ethnic patterns were observed from 1999 
onwards (appendix pp 19–20). Additionally, the incidence 
rates of ESRD hospital admission were higher in 
European patients with the highest deprivation scores 
than in those with the lowest deprivation scores; however, 
the incidence rates of this outcome were higher in Māori 
and Pacific patients overall than in the least deprived 
European patients (appendix pp 21–22).
Adjusted all-cause, cardiovascular, and cancer 
mortality rates, and incidence rates of cardiovascular, 
cancer and ESRD hospital admissions all increased with 
age (figure). The adjusted incidence rates of all six 
outcomes were highest among Māori patients aged older 
than 45 years, even after adjusting for birth cohort and 
period effects. Pacific patients generally had similar 
adjusted mortality rates as European patients, but had 
higher adjusted incidence rates of cardiovascular 
(45–80 years), cancer (60–75 years), and ESRD (≥45 years) 
hospital admissions. The incidence rates of ESRD hos p-
ital admissions in European patients showed a U-shaped 
association, and among those younger than 40 years, the 
incidence rates of ESRD hospital admissions were 
significantly higher in European patients than in Pacific 
patients. There was no significant birth cohort effect 
(IRR with the birth year of 1960 as a reference in each 
ethnic group), after adjusting for age and time period 
effects in each ethnic group.
Māori patients Pacific patients
Adjusted IRR (95% CI) Adjusted absolute risk difference 
per 1000 person-years (95% CI)
Adjusted IRR (95% CI) Adjusted absolute risk difference 
per 1000 person-years (95% CI)
All-cause mortality 1·96 (1·80 to 2·14) 22·85 (19·93 to 25·77) 1·04 (0·95 to 1·15) 1·00 (–0·12 to 2·13)
Cardiovascular mortality 1·93 (1·63 to 2·29) 6·97 (5·14 to 8·80) 0·87 (0·71 to 1·05) –1·00 (–1·56 to –0·44)
Cancer mortality 1·64 (1·40 to 1·93) 3·08 (2·25 to 3·92) 0·75 (0·62 to 0·91) –1·20 (–1·45 to –0·96)
Cardiovascular hospital admission 1·26 (1·25 to 1·28) 42·70 (41·32 to 44·08) 1·09 (1·07 to 1·10) 14·45 (13·70 to 15·20)
Cancer hospital admission 1·31 (1·28 to 1·34) 44·76 (42·37 to 47·15) 1·03 (1·00 to 1·06) 4·05 (2·81 to 5·30)
End-stage renal disease hospital 
admission
2·05 (1·96 to 2·14) 31·44 (29·67 to 33·21) 1·59 (1·52 to 1·67) 17·29 (16·12 to 18·46)
IRRs and absolute risk differences adjusted for sex, age group, Index of Multiple Deprivation, smoking status, obesity status, and time period. European ethnicity was used as 
the reference group. IRR=incidence rate ratio. 
Table 3: Adjusted IRRs and absolute risk differences for clinical outcomes in Māori and Pacific patients with type 2 diabetes compared with European 
patients with type 2 diabetes in New Zealand
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The adjusted time period effect (IRR with the 
calendar year of 2013 as reference in each ethnic group) was 
similar across the three ethnic groups, as the IRRs for all-
cause, cardiovascular, and cancer mortality first increased 
in the 1990s, reached a plateau in the 2000s, and then 
significantly decreased after 2013 (appendix pp 23–58). A 
continuously increasing trend in adjusted IRR for 
cardiovascular, cancer, and ESRD hospital admissions was 
observed over the whole study period (appendix pp 59–94). 
Similar age-period-cohort estimations for all outcomes 
were observed when patients were grouped by sex, socio-
economic status, smoking status, and obesity according to 
time of enrolment  (appendix pp 23–94).
Discussion
To our knowledge, this study is the first to compare 
all-cause, cardiovascular, and cancer mortality, and 
cardiovascular, cancer, and ESRD hospital admissions 
among Māori, Pacific, and European patients with type 2 
diabetes in New Zealand over 25 years, showing that 
disparities remain as marked now as they did almost 
25 years ago. The results show that Māori patients had 
worse outcomes than European New Zealander patients 
for all clinical outcomes measured. This difference was 
present after adjusting for age, sex, socioeconomic status, 
obesity, and smoking status. Although health disparities 
in cancer mortality and hospital admissions improved 
between 2014 and 2018, cardiovascular and ESRD 
outcomes have been consistently worse in Māori patients 
than in European patients for over 20 years. The incidence 
rates of ESRD and cardiovascular hospital admissions 
in Pacific patients were also higher than in European 
patients, although incidence rates of cancer-related out-
comes were lower, and rates of all-cause and cardiovascular 
mortality were similar. These results remained consistent 
when age-period-cohort models were used to estimate the 
incidence rates of health outcomes after adjusting for 
birth cohort and time period effects.
Higher IRRs for all-cause mortality (1·79–2·54), 
cardiovascular mortality (1·75–3·38), and cancer mortality 
(1·26-1·78) among Māori patients compared with the 
New Zealand general population between 1981 and 2011 
have been shown.12 In a cohort study of patients with type 2 
diabetes in South Auckland, standardised mortality ratios 
in European patients were 2·78 (95% CI 2·19–3·48), 6·55 
(4·61–9·03) in Māori patients, and 4·49 (3·07–6·34) in 
Pacific patients between 1991 and 1996, although the 
sample size was small and data were not adjusted for 
socioeconomic status.13 Data from a national primary 
health-care diabetes annual review programme (2000–05) 
found that, compared with European patients, the adjusted 
hazard ratios for the first cardiovascular event were 1·30 
(1·19–1·41) in Māori patients and 1·04 (0·95–1·13) in 
Pacific patients.13 Based on national prevalence data,14 these 
figures suggest that the annual number of extra deaths in 
Māori patients with type 2 diabetes in New Zealand was 
12 298 due to any cause, 4481 due to cardiovascular disease, 
and 2023 due to cancer.
Figure: Adjusted incidence rate (per 1000 person-years) of clinical outcomes in a New Zealand population with diabetes enrolled to the Diabetes Care 
Support Service between 1994 and 2018, by Māori, Pacific, and European ethnicity
Patients were aged 35–84 years. Period and birth cohort effects were adjusted by use of age-period-cohort models. Solid lines indicate point estimations and shaded 
areas indicate the 95% CIs.
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These findings raise two key questions. The first is 
about the effectiveness of diabetes-related policy for 
addressing health disparities and inequities for Māori 
and Pacific people over this time period. The second, 
more fundamental question, is why such substantial 
differences exist in all six outcomes between two 
Polynesian populations: Indigenous Māori and non-
Indigenous Pacific peoples.
Previous studies have attributed health disparities 
between Māori and European New Zealanders to several 
factors, including socioeconomic status,15 smoking,16 and 
obesity.17 However, the poorer outcomes in Māori patients 
compared with European patients in our study were 
independent of these variables. Health inequities through, 
for example, reduced access to care have also been 
suggested as a possible cause of health disparities;18,19 but 
we have previously shown that Māori (and Pacific) patients 
in this cohort had more diabetes consultations and similar 
or more screening tests than European patients.8 However, 
these consultations and screening tests could have been 
insufficient for their needs, and do not reflect, for example, 
health literacy or the cultural safety of the health care 
provided. Even though the prescription of statins, anti-
hypertensive, and anti hyperglycaemic drugs remained 
higher in Māori (and Pacific) patients than European 
patients, diastolic blood pressure, LDL cholesterol, and 
HbA1c were, on average, higher, which could have 
contributed to some of the excess risk. It has also been 
suggested that Māori patients are diagnosed later than 
European patients. However, in a study in the neighbouring 
Waikato district, the prevalence of retinopathy at diagnosis 
was low,20 as was the prevalence of undiagnosed diabetes,21 
suggesting that the delay between development and 
diagnosis of type 2 diabetes was small.
Pacific people arrived in New Zealand approximately 
1000–1200 years after Māori, and they have a similar 
genetic and cultural ancestry. Compared with Māori 
patients, Pacific patients in our study had the same or 
worse socioeconomic status, access to health care, and 
metabolic control, and a higher proportion of Pacific 
patients had obesity compared with Māori patients. 
Despite these disadvan tages, Pacific patients had largely 
similar mortality rates to European New Zealander 
patients after adjustment for sex, age group, IMD, 
smoking status, obesity status, and time period. This 
finding suggests that the worse outcomes among Māori 
patients are for reasons beyond these confounding factors. 
We speculate that there could be several possible reasons 
for this observation. Firstly, the adjustment measures are 
likely to be imperfect. NZDep13 as a measure of 
deprivation is thought to only reflect 50–75% of the actual 
socio economic status.10 Even though our comparison of 
the three NZDep measures indicated consistent stability 
in socioeconomic status in most patients, there is no 
annual measure of socio economic status, and a shifting 
socioeconomic status in a small number of patients might 
have led to a degree of information bias in some patients. 
Secondly, the proportion of patients reported as current 
smokers, which was higher in Māori patients than in 
European patients, could have been under-reported and 
under-recorded, and does not include smoking severity 
(eg, smoking pack-years). Finally, even though a higher 
BMI criterion for obesity is recom mended for Polynesian 
people,22 we used standard criteria, which is likely to 
attenuate the differences rather than enhance them; the 
effect would be expected to be similar among Māori and 
Pacific people.
One important difference between Pacific and Māori 
Polynesian populations is that a European heritage could 
contribute to the increased risk of some complications, 
without necessarily attenuating others (eg, ESRD); a 
factor that warrants further research. For example, 
European people have a higher frequency of a range of 
genes associated with cancer than several non-European 
ethnic groups.23 Whether these genes contributed to the 
increased mortality rates observed in Māori patients in 
our study is unclear. The excess risk of ESRD among 
Polynesian people appears to be a common feature 
between Māori and Pacific people,24 and was associated 
with a family history of renal disease, but not diabetes, 
among Polynesian people.25 Māori people could also be at 
greater risk of ESRD than other Polynesians because of 
their unique status as those who survived (or were 
selected for) the long oceanic journey to New Zealand.26 
A further mechanism is that Māori people have been 
affected by the colonisation process.6 This is a complex 
subject requiring further research that cannot be ignored.
Our study has several strengths, including being the 
largest study of a multi-ethnic cohort of patients with 
type 2 diabetes in New Zealand to report key diabetes-
related health outcomes over 25 years. The cohort included 
all patients from participating general practices. By linking 
large, nationally representative databases, we were able to 
follow up patients to ascertain all incident health outcomes, 
including cause-specific mortality and hospital admissions. 
All health outcomes used in this study were based on the 
linkage of specific registration datasets, which provided 
good validation of outcomes. The accuracy of clinical 
recording and diagnoses in this study have been validated 
for a range of comorbidities, and we also used primary 
ICD codes for cause-specific outcomes, which have high 
precision.27 The study limitations include heterogeneity in 
the Pacific, Māori, and European populations, and the 
national repre sentativeness of the population and of the 
participating general practices. However, the population 
covered by the DCSS includes a substantial proportion of 
Pacific and Māori populations in New Zealand, and 
possibly European people at higher risk of diabetes 
complications due to their lower socioeconomic status 
overall. The high incidence rate of ESRD hospital 
admissions among younger (ie, aged <40 years) European 
patients suggests that people with type 1 diabetes were also 
included in the cohort. Misdiagnosis of type 1 diabetes as 
type 2 diabetes is a well known issue in primary care,28 
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although this would probably have attenuated the observed 
differences between ethnic groups.
In conclusion, population-level ethnic disparities in 
type 2 diabetes outcomes are a major and persistent 
public health challenge in New Zealand. Over the past 
two decades, poor outcomes have persisted among Māori 
and Pacific people with type 2 diabetes after adjusting 
for age, sex, smoking, obesity, socioeconomic status, time 
period, and birth cohort effects. The perpetuation of these 
poorer outcomes among Māori and Pacific patients with 
type 2 diabetes compared with European patients over 
such a long period of time calls for the introduction of 
new, more intensive approaches to prevention, early 
recognition, and management of type 2 diabetes, while 
broader strategies are needed to address social disparities. 
Research into the biological and societal mechanisms 
underlying these disparities, and the diff erences in 
outcomes between Māori and Pacific patients with type 2 
diabetes is needed.
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